Chemicals · Founded 1998 · www.nfil.in · BSE 532504 · NSE NAVIN FLUORI · ISIN INE048G01026
No Notes Added Yet
Business
Navin Fluorine International Ltd. (NFIL) is a leading Indian manufacturer of fluorochemicals. The company operates across a diversified portfolio including Specialty Chemicals, Refrigerants, Inorganic Fluorides, and Contract Development and Manufacturing Organization (CDMO/CSM) services. Its core business model involves leveraging its expertise in fluorine chemistry to develop and produce high-value products and intermediates. NFIL makes money by selling these fluorinated products to a wide range of industries globally, including pharmaceuticals, agrochemicals, automotive, electronics, air conditioning, and industrial applications.
Revenue Mix
Navin Fluorine typically reports revenue across these key segments:
Specialty Chemicals: This segment includes intermediates for pharmaceuticals, agrochemicals, and other industrial applications. It is often a high-growth area for the company, driven by complex chemistry and custom synthesis.
CDMO / CSM (Contract Development & Manufacturing Services): NFIL provides custom manufacturing services to global pharmaceutical and agrochemical majors, involving process development, scale-up, and commercial manufacturing of complex fluorinated molecules. This segment is strategically important due to its high-value nature and long-term client relationships.
Refrigerants: Manufactures various types of refrigerants (e.g., HCFCs, HFCs, and newer generation HFOs) for air conditioning and refrigeration industries.
Inorganic Fluorides: Produces a range of inorganic fluorides used in diverse industries like glass, steel, and aluminum.
While specific revenue percentages fluctuate with market dynamics and new project ramp-ups, Specialty Chemicals and CDMO are increasingly significant contributors to growth and profitability.
Industry
The fluorochemicals industry is highly specialized, capital-intensive, and technology-driven, with stringent quality and regulatory requirements. India is emerging as a significant manufacturing hub for specialty chemicals and CDMO. Navin Fluorine is one of India's largest and most diversified integrated fluorochemical manufacturers. It holds a strong competitive position domestically due to its extensive product portfolio, technical capabilities, and vertical integration (from basic raw materials like fluorspar). Globally, it competes with specialized chemical companies, particularly in the CDMO space, by offering cost-effective and high-quality solutions.
MOAT
Technological Expertise & R&D: Deep expertise in complex fluorine chemistry, supported by strong in-house R&D capabilities, allows for the development of new processes and products, including complex molecules for CDMO clients.
Vertical Integration: Backward integration from basic raw materials to specialized fluorinated products provides cost advantages, supply security, and quality control.
Diversified Product Portfolio & End Markets: Reduces reliance on any single product or industry, offering stability and resilience.
Long-term Client Relationships (CDMO): Established trust and partnerships with global pharmaceutical and agrochemical companies lead to repeat business and multi-year contracts.
High Entry Barriers: Significant capital expenditure, specialized technical know-how, and environmental/regulatory clearances make it difficult for new entrants.
Growth Drivers
Expansion of CDMO/CSM Business: Global outsourcing trend by pharma and agrochemical majors to India, coupled with NFIL's strong execution and new capacity additions (e.g., Dahej multi-purpose plant), will drive growth.
Increasing Demand for Specialty Fluorochemicals: Growth in end-user industries like electronics, EVs, new energy, and advanced materials will fuel demand for NFIL's high-performance specialty products.
Transition to Newer Generation Refrigerants: Global phasing out of high Global Warming Potential (GWP) refrigerants creates opportunities for NFIL to develop and supply environmentally friendlier alternatives.
"Make in India" & Import Substitution: Government initiatives and global supply chain diversification are boosting domestic manufacturing, benefiting NFIL.
Capacity Expansion: Ongoing strategic capital expenditure projects are aimed at enhancing capacities across key segments to cater to future demand.
Risks
Raw Material Price Volatility: Fluctuations in the prices of key raw materials like fluorspar, and other basic chemicals, can impact profitability.
Environmental & Regulatory Risks: Stringent and evolving environmental regulations (especially concerning fluorochemicals and refrigerants like GWP norms) can necessitate significant capital investment or restrict operations.
Technological Obsolescence: Rapid advancements in chemistry or alternative technologies could render existing products or processes less competitive.
Client Concentration: While CDMO offers stability, reliance on a few large global clients can pose a risk if contracts are not renewed or volumes decrease.
Forex Fluctuations: Significant export revenues and import of raw materials expose the company to currency exchange rate volatility.
Project Execution Risks: Delays or cost overruns in large capital expenditure projects can impact financial performance and growth timelines.
Competition: Intense competition from both domestic and international players, particularly from China, could exert pressure on pricing and margins.
Management & Ownership
Navin Fluorine is part of the Padmanabh Mafatlal Group, which serves as the promoter group, holding a significant stake in the company. The company is professionally managed with a blend of experienced industry veterans and a focus on corporate governance. The management team has a track record of strategic investments in R&D and capacity expansion, focusing on high-value segments like CDMO. The ownership structure typically includes the promoter group, institutional investors (domestic and foreign), and public shareholders.
Outlook
Navin Fluorine is strategically positioned to capitalize on global megatrends, particularly the outsourcing of complex chemical manufacturing to India and the increasing demand for advanced fluorinated materials. The CDMO segment, supported by robust R&D and new capacity, is expected to be a key growth driver, offering higher margins and stable revenue streams. The specialty chemicals portfolio also presents significant growth avenues across diverse end-user industries. However, the company faces inherent risks associated with raw material price volatility, evolving environmental regulations, and intense global competition. Successful execution of ongoing large-scale capital expenditure projects and effective navigation of regulatory landscapes will be crucial for sustained growth and profitability.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 500 | 602 | 524 | 519 | 606 | 701 | 725 | 758 | 892 | 938 |
| Other Income | 12 | 13 | 10 | 11 | 10 | 12 | 14 | 18 | 16 | 18 |
| Total Income | 512 | 614 | 534 | 530 | 617 | 713 | 739 | 777 | 908 | 955 |
| Total Expenditure | 424 | 492 | 423 | 411 | 459 | 522 | 519 | 512 | 585 | 617 |
| Operating Profit | 88 | 123 | 111 | 119 | 158 | 191 | 221 | 264 | 323 | 339 |
| Interest | 18 | 17 | 16 | 14 | 20 | 28 | 30 | 30 | 28 | 29 |
| Depreciation | 25 | 26 | 27 | 28 | 30 | 35 | 35 | 37 | 36 | 41 |
| Exceptional Income / Expenses | 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -20 | 14 |
| Profit Before Tax | 97 | 79 | 68 | 77 | 108 | 127 | 155 | 198 | 238 | 282 |
| Provision for Tax | 19 | 9 | 17 | 18 | 24 | 32 | 38 | 49 | 53 | 70 |
| Profit After Tax | 78 | 70 | 51 | 59 | 84 | 95 | 117 | 148 | 185 | 213 |
| Adjustments | 0 | -0 | 0 | 0 | 0 | -0 | -0 | 0 | 0 | 0 |
| Profit After Adjustments | 78 | 70 | 51 | 59 | 84 | 95 | 117 | 148 | 185 | 213 |
| Adjusted Earnings Per Share | 15.7 | 14.2 | 10.3 | 11.9 | 16.9 | 19.1 | 23.6 | 29 | 36.2 | 41.5 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 592 | 680 | 742 | 913 | 996 | 1062 | 1179 | 1453 | 2077 | 2065 | 2349 | 3313 |
| Other Income | 30 | 24 | 56 | 93 | 34 | 33 | 79 | 39 | 36 | 56 | 44 | 66 |
| Total Income | 621 | 704 | 797 | 1005 | 1030 | 1095 | 1258 | 1493 | 2113 | 2121 | 2393 | 3379 |
| Total Expenditure | 519 | 562 | 583 | 698 | 778 | 798 | 870 | 1099 | 1527 | 1667 | 1816 | 2233 |
| Operating Profit | 102 | 142 | 215 | 307 | 253 | 297 | 388 | 394 | 586 | 454 | 577 | 1147 |
| Interest | 3 | 4 | 3 | 1 | 1 | 2 | 2 | 2 | 28 | 75 | 78 | 117 |
| Depreciation | 20 | 22 | 30 | 40 | 28 | 37 | 44 | 48 | 63 | 96 | 119 | 149 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 16 | 0 | 0 | 52 | 0 | -6 |
| Profit Before Tax | 78 | 116 | 182 | 266 | 224 | 258 | 358 | 344 | 496 | 336 | 380 | 873 |
| Provision for Tax | 20 | 32 | 45 | 84 | 77 | -144 | 111 | 81 | 121 | 65 | 91 | 210 |
| Profit After Tax | 58 | 84 | 137 | 182 | 147 | 401 | 247 | 263 | 375 | 271 | 289 | 663 |
| Adjustments | -4 | -0 | -0 | -3 | 2 | 7 | 10 | -0 | -0 | -0 | -0 | 0 |
| Profit After Adjustments | 55 | 84 | 137 | 180 | 149 | 409 | 258 | 263 | 375 | 271 | 289 | 663 |
| Adjusted Earnings Per Share | 11.2 | 17.1 | 27.9 | 36.4 | 30.2 | 82.6 | 52 | 53.1 | 75.7 | 54.6 | 58.2 | 130.3 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 14% | 17% | 17% | 15% |
| Operating Profit CAGR | 27% | 14% | 14% | 19% |
| PAT CAGR | 7% | 3% | -6% | 17% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 61% | 15% | 17% | 32% |
| ROE Average | 12% | 14% | 15% | 17% |
| ROCE Average | 12% | 15% | 18% | 19% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 588 | 645 | 835 | 983 | 1072 | 1412 | 1634 | 1844 | 2185 | 2383 | 2626 |
| Minority's Interest | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 27 | 48 | 11 | 4 | 0 | 0 | 0 | 100 | 753 | 1023 | 1053 |
| Other Non-Current Liabilities | 254 | 280 | 270 | 249 | 251 | 408 | 348 | 355 | 460 | 418 | 467 |
| Total Current Liabilities | 225 | 264 | 375 | 390 | 426 | 177 | 367 | 554 | 704 | 937 | 1142 |
| Total Liabilities | 1107 | 1236 | 1491 | 1626 | 1750 | 1997 | 2348 | 2854 | 4103 | 4761 | 5289 |
| Fixed Assets | 274 | 375 | 503 | 370 | 374 | 474 | 486 | 503 | 1594 | 1824 | 2687 |
| Other Non-Current Assets | 461 | 447 | 426 | 513 | 566 | 746 | 502 | 1161 | 940 | 1233 | 786 |
| Total Current Assets | 372 | 414 | 562 | 743 | 810 | 778 | 1360 | 1190 | 1567 | 1704 | 1816 |
| Total Assets | 1107 | 1236 | 1491 | 1626 | 1750 | 1997 | 2348 | 2854 | 4103 | 4761 | 5289 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 27 | 10 | 14 | 24 | 18 | 16 | 177 | 132 | 76 | 14 | 7 |
| Cash Flow from Operating Activities | 1 | 76 | 92 | 169 | 90 | 157 | 237 | 75 | -64 | 750 | 571 |
| Cash Flow from Investing Activities | 3 | -53 | -16 | -136 | -24 | 85 | -237 | -172 | -656 | -1094 | -511 |
| Cash Flow from Financing Activities | -21 | -17 | -67 | -39 | -68 | -81 | -45 | 42 | 658 | 336 | -47 |
| Net Cash Inflow / Outflow | -17 | 6 | 10 | -6 | -3 | 161 | -45 | -56 | -61 | -8 | 13 |
| Closing Cash & Cash Equivalent | 10 | 16 | 24 | 18 | 16 | 177 | 132 | 76 | 14 | 7 | 20 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 11.17 | 17.07 | 27.91 | 36.43 | 30.15 | 82.58 | 52.02 | 53.09 | 75.72 | 54.59 | 58.18 |
| CEPS(Rs) | 16.04 | 21.66 | 34.09 | 45.04 | 35.38 | 88.6 | 58.83 | 62.76 | 88.36 | 74 | 82.26 |
| DPS(Rs) | 3.2 | 4.2 | 6.3 | 10 | 7.8 | 11 | 11 | 11 | 12 | 15 | 12 |
| Book NAV/Share(Rs) | 120.32 | 131.89 | 170.15 | 198.89 | 216.43 | 284.87 | 329.56 | 371.93 | 437.4 | 477.01 | 524.57 |
| Core EBITDA Margin(%) | 11.47 | 16.25 | 20.26 | 23.23 | 21.92 | 24.82 | 26.22 | 24.41 | 26.49 | 19.29 | 22.72 |
| EBIT Margin(%) | 12.96 | 16.53 | 23.58 | 28.93 | 22.62 | 24.47 | 30.5 | 23.82 | 25.2 | 19.86 | 19.5 |
| Pre Tax Margin(%) | 12.43 | 16.01 | 23.24 | 28.8 | 22.53 | 24.29 | 30.34 | 23.69 | 23.87 | 16.25 | 16.18 |
| PAT Margin (%) | 9.25 | 11.57 | 17.49 | 19.72 | 14.8 | 37.81 | 20.95 | 18.1 | 18.06 | 13.1 | 12.28 |
| Cash Profit Margin (%) | 12.44 | 14.68 | 21.31 | 24.02 | 17.57 | 41.29 | 24.69 | 21.4 | 21.08 | 17.76 | 17.37 |
| ROA(%) | 5.45 | 7.13 | 10.04 | 11.71 | 8.74 | 21.42 | 11.37 | 10.11 | 10.79 | 6.1 | 5.74 |
| ROE(%) | 10.19 | 13.54 | 18.53 | 20.11 | 14.37 | 32.37 | 16.25 | 15.14 | 18.71 | 11.94 | 11.62 |
| ROCE(%) | 12.93 | 17.35 | 23.37 | 28.94 | 21.73 | 20.87 | 23.58 | 19.31 | 21.01 | 12.14 | 11.76 |
| Receivable days | 60.96 | 68.37 | 67.15 | 57.82 | 60.16 | 67.26 | 77.77 | 80.59 | 80.75 | 94.92 | 85.05 |
| Inventory Days | 41.05 | 38.32 | 43.87 | 44.69 | 41.37 | 46.38 | 52.34 | 54.99 | 63.75 | 74.22 | 53.92 |
| Payable days | 94.65 | 108.36 | 104.15 | 84.23 | 68.18 | 68.13 | 73.45 | 73.36 | 82.13 | 110.39 | 113.74 |
| PER(x) | 14.98 | 19.83 | 21.81 | 21.16 | 23.59 | 14.83 | 52.86 | 76.89 | 56.33 | 57.01 | 72.33 |
| Price/Book(x) | 1.39 | 2.57 | 3.58 | 3.88 | 3.29 | 4.3 | 8.34 | 10.98 | 9.75 | 6.52 | 8.02 |
| Dividend Yield(%) | 1.91 | 1.24 | 1.03 | 1.3 | 1.1 | 0.9 | 0.4 | 0.27 | 0.28 | 0.48 | 0.29 |
| EV/Net Sales(x) | 1.44 | 2.51 | 3.99 | 4.14 | 3.5 | 5.45 | 11.08 | 13.92 | 10.57 | 8.1 | 9.48 |
| EV/Core EBITDA(x) | 8.36 | 12.05 | 13.77 | 12.29 | 13.78 | 19.48 | 33.66 | 51.36 | 37.45 | 36.84 | 38.57 |
| Net Sales Growth(%) | 21.65 | 14.9 | 9.1 | 23.09 | 9.12 | 6.59 | 11.1 | 23.23 | 42.94 | -0.6 | 13.77 |
| EBIT Growth(%) | 8.84 | 46.26 | 54.78 | 44.92 | -15.86 | 15.35 | 38.43 | -3.76 | 51.21 | -21.65 | 11.69 |
| PAT Growth(%) | 6.5 | 43.39 | 64.01 | 33.22 | -19.19 | 172.21 | -38.45 | 6.49 | 42.61 | -27.9 | 6.69 |
| EPS Growth(%) | -17.07 | 52.76 | 63.52 | 30.56 | -17.24 | 173.89 | -37 | 2.05 | 42.62 | -27.9 | 6.58 |
| Debt/Equity(x) | 0.1 | 0.13 | 0.02 | 0.01 | 0 | 0 | 0 | 0.06 | 0.39 | 0.57 | 0.55 |
| Current Ratio(x) | 1.65 | 1.57 | 1.5 | 1.91 | 1.9 | 4.39 | 3.7 | 2.15 | 2.22 | 1.82 | 1.59 |
| Quick Ratio(x) | 1.31 | 1.28 | 1.2 | 1.62 | 1.64 | 3.5 | 3.21 | 1.68 | 1.56 | 1.42 | 1.31 |
| Interest Cover(x) | 24.48 | 31.58 | 68.48 | 224.36 | 272.39 | 129.62 | 195.47 | 182.17 | 19.02 | 5.5 | 5.88 |
| Total Debt/Mcap(x) | 0.08 | 0.05 | 0.01 | 0 | 0 | 0 | 0 | 0.01 | 0.04 | 0.09 | 0.07 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 28.81 | 28.81 | 28.8 | 28.44 | 28.44 | 28.44 | 28.01 | 27.12 | 27.11 | 27.11 |
| FII | 15.92 | 15.57 | 18.02 | 18.23 | 18.55 | 20.16 | 21.55 | 22.15 | 23.74 | 23.78 |
| DII | 28.92 | 28.6 | 27.28 | 28.18 | 28.46 | 30.04 | 28.7 | 29.57 | 28.09 | 27.62 |
| Public | 26.35 | 27.02 | 25.89 | 25.16 | 24.56 | 21.37 | 21.74 | 21.16 | 21.06 | 21.49 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.43 | 1.43 | 1.43 | 1.41 | 1.41 | 1.41 | 1.39 | 1.39 | 1.39 | 1.39 |
| FII | 0.79 | 0.77 | 0.89 | 0.9 | 0.92 | 1 | 1.07 | 1.13 | 1.22 | 1.22 |
| DII | 1.43 | 1.42 | 1.35 | 1.4 | 1.41 | 1.49 | 1.42 | 1.51 | 1.44 | 1.42 |
| Public | 1.31 | 1.34 | 1.28 | 1.25 | 1.22 | 1.06 | 1.08 | 1.08 | 1.08 | 1.1 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4.96 | 4.96 | 4.96 | 4.96 | 4.96 | 4.96 | 4.96 | 5.12 | 5.12 | 5.12 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +14% | +17% | +17% | +15% |
| Operating Profit CAGR | +27% | +14% | +14% | +19% |
| PAT CAGR | +7% | +3% | -6% | +17% |
| Share Price CAGR | +61% | +15% | +17% | +32% |
| ROE Average | +12% | +14% | +15% | +17% |
| ROCE Average | +12% | +15% | +18% | +19% |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 28.81 | 28.81 | 28.8 | 28.44 | 28.44 | 28.44 | 28.01 | 27.12 | 27.11 | 27.11 |
| FII | 15.92 | 15.57 | 18.02 | 18.23 | 18.55 | 20.16 | 21.55 | 22.15 | 23.74 | 23.78 |
| DII | 28.92 | 28.6 | 27.28 | 28.18 | 28.46 | 30.04 | 28.7 | 29.57 | 28.09 | 27.62 |
| Public | 71.19 | 71.19 | 71.2 | 71.56 | 71.56 | 71.56 | 71.99 | 72.88 | 72.89 | 72.89 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.43 | 1.43 | 1.43 | 1.41 | 1.41 | 1.41 | 1.39 | 1.39 | 1.39 | 1.39 |
| FII | 0.79 | 0.77 | 0.89 | 0.9 | 0.92 | 1 | 1.07 | 1.13 | 1.22 | 1.22 |
| DII | 1.43 | 1.42 | 1.35 | 1.4 | 1.41 | 1.49 | 1.42 | 1.51 | 1.44 | 1.42 |
| Public | 3.53 | 3.53 | 3.53 | 3.55 | 3.55 | 3.55 | 3.57 | 3.73 | 3.74 | 3.74 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4.96 | 4.96 | 4.96 | 4.96 | 4.96 | 4.96 | 4.96 | 5.12 | 5.12 | 5.12 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.